Below are the most recent publications written about "Methotrexate" by people in Profiles.
-
Benatti HR, Taghian T, Mihalek O, Nath S, Gallagher J, McElroy A, Hall EF, Daci R, Yingling NK, Baker WC, Tuominen S, Bierfeldt L, Jiang X, Gray-Edwards HL, Sirianni RW. Cerebrospinal Fluid Flow Enhancement (CFE) Increases the Spatial Distribution of Methotrexate after Intracerebroventricular Administration in a Sheep Model. Mol Pharm. 2025 Jul 07; 22(7):3654-3665.
-
D'Ambrosio ES, Allen MD, Ozes B, Sahenk Z. Concurrent nodular lymphocytic myositis and myasthenia gravis. A case report. Neuromuscul Disord. 2024 Dec; 45:105211.
-
Xiang Y, Pan BH, Zhang J, Chen JQ, Fang H, Wang Q, Li LH, Chen TS, Chen JX, Li C, Zheng XF, Zhu SH. Suppression of overactivated immunity in the early stage is the key to improve the prognosis in severe burns. Front Immunol. 2024; 15:1455899.
-
Sun A, Hagenbuch B, Kelly EJ, Wang J. Molecular Mechanisms of Organic Anion Transporting Polypeptide-Mediated Organic Anion Clearance at the Blood-Cerebrospinal Fluid Barrier. Mol Pharmacol. 2023 12; 104(6):255-265.
-
Jiang F, Mao MY, Xiang Y, Lu X, Guan CL, Jiao LZ, Wan XR, Feng FZ, Ren T, Yang JJ, Zhao J. Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0-4): study protocol for a prospective, multicentre, randomized trial. BMC Cancer. 2023 Aug 23; 23(1):784.
-
Bharadwaj R, Lusi CF, Mashayekh S, Nagar A, Subbarao M, Kane GI, Wodzanowski KA, Brown AR, Okuda K, Monahan A, Paik D, Nandy A, Anonick MV, Goldman WE, Kanneganti TD, Orzalli MH, Grimes CL, Atukorale PU, Silverman N. Methotrexate suppresses psoriatic skin inflammation by inhibiting muropeptide transporter SLC46A2 activity. Immunity. 2023 05 09; 56(5):998-1012.e8.
-
Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S, Karis E, Solomon DH. Examining the potential direct cardiovascular benefit of tumor-necrosis factor inhibitor in rheumatoid arthritis: Natural and controlled direct effect analyses. Pharmacoepidemiol Drug Saf. 2023 04; 32(4):407-415.
-
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Ros?e P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, G?rl?v JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022 07; 36(7):1870-1878.
-
Kremer JM, Reed G, Pappas DA, Kane K, Feathers VL, Weinblatt ME, Shadick N, Greenberg J, Harrold LL. Dr. Kremer et al reply. J Rheumatol. 2022 03; 49(3):338-339.
-
Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1114-1124.